Targeting STEAP1 as an anticancer strategy

Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of i...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-10, Vol.13, p.1285661-1285661
Main Authors: Nakamura, Hajime, Arihara, Yohei, Takada, Kohichi
Format: Article
Language:English
Subjects:
antibody therapy
anticancer strategies
cancer vaccine
CAR-T therapy
Oncology
STEAP1
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c395t-3e4932fe474a79900a64f367bdde72ba117c2c6a6cfac382d6e127477c10396e3
container_end_page 1285661
container_issue
container_start_page 1285661
container_title Frontiers in oncology
container_volume 13
creator Nakamura, Hajime
Arihara, Yohei
Takada, Kohichi
description Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of its tumor specificity and membrane-bound localization. The clinical efficacy of an antibody-drug conjugate targeting STEAP1 in metastatic, castration-resistant, prostate cancer was demonstrated in a phase 1 trial. Furthermore, growing evidence suggests that STEAP1 is an attractive target for immunotherapies such as chimeric antigen receptor-T cell therapy. In this review, we summarize the oncogenic functions of STEAP1 by cancer type. This review also provides new insights into the development of new anticancer strategies targeting STEAP1.
doi_str_mv 10.3389/fonc.2023.1285661
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a69def6b55f844a0accb364867bf0331</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a69def6b55f844a0accb364867bf0331</doaj_id><sourcerecordid>2885207458</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-3e4932fe474a79900a64f367bdde72ba117c2c6a6cfac382d6e127477c10396e3</originalsourceid><addsrcrecordid>eNpVkW9LwzAQxoMoOHQfwHd9KcJm_jVpX8kYUwcDBSf4LlzTS-3o2pl0wr69mRviwkGOy_F77vIQcsPoWIgsv3dda8eccjFmPEuVYmdkwLmQo1yKj_N_-SUZhrCi8aiUMioG5G4JvsK-bqvkbTmbvLIEQgJtjL620Fr0Seg99FjtrsmFgybg8HhfkffH2XL6PFq8PM2nk8XIijztRwJlLrhDqSXoPKcUlHRC6aIsUfMCGNOWWwXKOrAi46VCxrXU2saBcoXiiswP3LKDldn4eg1-ZzqozW-h85UBH6dr0IDKS3SqSFOXSQkUrC2EkllUc1QIFlkPB9ZmW6yxtNjGZZoT6OlLW3-aqvs2jCoWv5ZGwu2R4LuvLYberOtgsWmgxW4bDM-ylFMt0yy2skOr9V0IHt2fDqNmb5TZG2X2RpmjUeIHea2F-g</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2885207458</pqid></control><display><type>article</type><title>Targeting STEAP1 as an anticancer strategy</title><source>PubMed Central</source><creator>Nakamura, Hajime ; Arihara, Yohei ; Takada, Kohichi</creator><creatorcontrib>Nakamura, Hajime ; Arihara, Yohei ; Takada, Kohichi</creatorcontrib><description>Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of its tumor specificity and membrane-bound localization. The clinical efficacy of an antibody-drug conjugate targeting STEAP1 in metastatic, castration-resistant, prostate cancer was demonstrated in a phase 1 trial. Furthermore, growing evidence suggests that STEAP1 is an attractive target for immunotherapies such as chimeric antigen receptor-T cell therapy. In this review, we summarize the oncogenic functions of STEAP1 by cancer type. This review also provides new insights into the development of new anticancer strategies targeting STEAP1.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2023.1285661</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><subject>antibody therapy ; anticancer strategies ; cancer vaccine ; CAR-T therapy ; Oncology ; STEAP1</subject><ispartof>Frontiers in oncology, 2023-10, Vol.13, p.1285661-1285661</ispartof><rights>Copyright © 2023 Nakamura, Arihara and Takada 2023 Nakamura, Arihara and Takada</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c395t-3e4932fe474a79900a64f367bdde72ba117c2c6a6cfac382d6e127477c10396e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613890/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613890/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Nakamura, Hajime</creatorcontrib><creatorcontrib>Arihara, Yohei</creatorcontrib><creatorcontrib>Takada, Kohichi</creatorcontrib><title>Targeting STEAP1 as an anticancer strategy</title><title>Frontiers in oncology</title><description>Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of its tumor specificity and membrane-bound localization. The clinical efficacy of an antibody-drug conjugate targeting STEAP1 in metastatic, castration-resistant, prostate cancer was demonstrated in a phase 1 trial. Furthermore, growing evidence suggests that STEAP1 is an attractive target for immunotherapies such as chimeric antigen receptor-T cell therapy. In this review, we summarize the oncogenic functions of STEAP1 by cancer type. This review also provides new insights into the development of new anticancer strategies targeting STEAP1.</description><subject>antibody therapy</subject><subject>anticancer strategies</subject><subject>cancer vaccine</subject><subject>CAR-T therapy</subject><subject>Oncology</subject><subject>STEAP1</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkW9LwzAQxoMoOHQfwHd9KcJm_jVpX8kYUwcDBSf4LlzTS-3o2pl0wr69mRviwkGOy_F77vIQcsPoWIgsv3dda8eccjFmPEuVYmdkwLmQo1yKj_N_-SUZhrCi8aiUMioG5G4JvsK-bqvkbTmbvLIEQgJtjL620Fr0Seg99FjtrsmFgybg8HhfkffH2XL6PFq8PM2nk8XIijztRwJlLrhDqSXoPKcUlHRC6aIsUfMCGNOWWwXKOrAi46VCxrXU2saBcoXiiswP3LKDldn4eg1-ZzqozW-h85UBH6dr0IDKS3SqSFOXSQkUrC2EkllUc1QIFlkPB9ZmW6yxtNjGZZoT6OlLW3-aqvs2jCoWv5ZGwu2R4LuvLYberOtgsWmgxW4bDM-ylFMt0yy2skOr9V0IHt2fDqNmb5TZG2X2RpmjUeIHea2F-g</recordid><startdate>20231016</startdate><enddate>20231016</enddate><creator>Nakamura, Hajime</creator><creator>Arihara, Yohei</creator><creator>Takada, Kohichi</creator><general>Frontiers Media S.A</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20231016</creationdate><title>Targeting STEAP1 as an anticancer strategy</title><author>Nakamura, Hajime ; Arihara, Yohei ; Takada, Kohichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-3e4932fe474a79900a64f367bdde72ba117c2c6a6cfac382d6e127477c10396e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>antibody therapy</topic><topic>anticancer strategies</topic><topic>cancer vaccine</topic><topic>CAR-T therapy</topic><topic>Oncology</topic><topic>STEAP1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Hajime</creatorcontrib><creatorcontrib>Arihara, Yohei</creatorcontrib><creatorcontrib>Takada, Kohichi</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Hajime</au><au>Arihara, Yohei</au><au>Takada, Kohichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting STEAP1 as an anticancer strategy</atitle><jtitle>Frontiers in oncology</jtitle><date>2023-10-16</date><risdate>2023</risdate><volume>13</volume><spage>1285661</spage><epage>1285661</epage><pages>1285661-1285661</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of its tumor specificity and membrane-bound localization. The clinical efficacy of an antibody-drug conjugate targeting STEAP1 in metastatic, castration-resistant, prostate cancer was demonstrated in a phase 1 trial. Furthermore, growing evidence suggests that STEAP1 is an attractive target for immunotherapies such as chimeric antigen receptor-T cell therapy. In this review, we summarize the oncogenic functions of STEAP1 by cancer type. This review also provides new insights into the development of new anticancer strategies targeting STEAP1.</abstract><pub>Frontiers Media S.A</pub><doi>10.3389/fonc.2023.1285661</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-943X
ispartof Frontiers in oncology, 2023-10, Vol.13, p.1285661-1285661
issn 2234-943X
2234-943X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a69def6b55f844a0accb364867bf0331
source PubMed Central
subjects antibody therapy
anticancer strategies
cancer vaccine
CAR-T therapy
Oncology
STEAP1
title Targeting STEAP1 as an anticancer strategy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T06%3A54%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20STEAP1%20as%20an%20anticancer%20strategy&rft.jtitle=Frontiers%20in%20oncology&rft.au=Nakamura,%20Hajime&rft.date=2023-10-16&rft.volume=13&rft.spage=1285661&rft.epage=1285661&rft.pages=1285661-1285661&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2023.1285661&rft_dat=%3Cproquest_doaj_%3E2885207458%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c395t-3e4932fe474a79900a64f367bdde72ba117c2c6a6cfac382d6e127477c10396e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2885207458&rft_id=info:pmid/&rfr_iscdi=true